EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review

Qiongqian Li; Tongze Cai; Xiaoming Zheng; Shunrong Zhang; Chanjuan Li; Huang Tang; Zhiyong Yu; Jianlong Zhou

doi:10.1002/ccr3.70043

EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review

Clin Case Rep. 2025 Jan 7;13(1):e70043. doi: 10.1002/ccr3.70043. eCollection 2025 Jan.

Authors

Qiongqian Li¹, Tongze Cai¹, Xiaoming Zheng¹, Shunrong Zhang¹, Chanjuan Li¹, Huang Tang¹, Zhiyong Yu¹, Jianlong Zhou¹

Affiliation

¹ Department of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.

Abstract

We report a case showing that lorlatinib is effective in treating EML4-ALK-positive low-grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ovarian cancer patients with EML4-ALK fusion and promoting new ideas for the study of EML4-ALK targets in ovarian cancer.

Keywords: EML4‐ALK fusion gene; intracranial metastasis; lorlatinib; ovarian cancer.